PhRMA Urges Fed. Circ. To Rethink Novo Patent Obviousness
PhRMA, which represents brand-name drugmakers, asserted that a 2-1 decision in June distorted the court’s own standards for an “obvious to try” argument that in this case sought to strike down a method patent for combining Prandin, or repaglinide, with metformin.
Development of useful...
To view the full article, register now.